The writing has been on the wall for at least a decade when you delve deep into the preclinical research done on the pathophysiological mechanisms underlying neurodegenerative disorders.
We can see from this discussion that the amyloid hypothesis for AD is wrong on multiple reasons. I feel that once the general market accepts defeat, the move towards new hypotheses - how dysregulation of proteostasis may contribute to development of neurodegenerative conditions in the elderly or in other situations - may lead to AD or other seemingly different disorders.
Look who has been early in this realm - with the first possible therapeutic testing the "restoration of homeostasis" theory - it is Anavex!
We will be bashed, laughed at and told that we are fools for investing in this. The share price languishment will be pointed out as "proof" that the market knows that Anavex is a failure.
Yet - how many times have we seen the market incorrectly assume companies, in early stage development, go no where. How many times do we see nervous nellies getting out at any hint of further risk (and yes, this is a VERY risky assessment).
But now with the guideline release - I expect within the next few months, Anavex to start churning out PRs and annoucement of results. Perhaps, in the 2nd half of this year - Anavex will begin ascending once the amyloid hypothesis is completely defeated.
Market Data 
Markets 
AI
